MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi

By Heather Cartwright

Pharma Deals Review: Vol 2014 Issue 9 (Table of Contents)

Published: 24 Sep-2014

DOI: 10.3833/pdr.v2014.i9.2062     ISSN: 1756-7874

Section: Distribution & Marketing

Fulltext:

Abstract

Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details